Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.40 |
| ▸ | AHR | P35869 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717703 | 0.84 | MCL1 (0.48) | MCL1KCNH2MAOBADORA3AHR | |
| SCHEMBL719532 | 0.82 | KDM4E (0.51) | POLBKDM4EALDH1A1RAB9ANQO1 | |
| SCHEMBL12248491 | 0.81 | MCL1 (0.53) | MCL1KCNH2MAOBADORA3AHR | |
| Ammonia Solution, Strong SCHEMBL29224921 | 0.73 | MCL1 (0.48) | MCL1KCNH2MAOBADORA3AHR | |
| SCHEMBL716872 | 0.72 | MCL1 (0.47) | MCL1KCNH2MAOBPOLBKDM4E | |
| SCHEMBL24756052 | 0.71 | MCL1 (0.46) | MCL1KCNH2MAOBADORA3AHR | |
| SCHEMBL721218 | 0.70 | MCL1 (0.43) | MCL1KCNH2AHRALDH1A1AKR1B1 | |
| SCHEMBL14409919 | 0.70 | MCL1 (0.59) | MCL1KCNH2ADORA3AHRKDM4E | |
| SCHEMBL4449382 | 0.67 | MCL1 (0.56) | MCL1KCNH2MAOBADORA3AHR | |
| SCHEMBL25824628 | 0.67 | MCL1 (0.56) | MCL1KCNH2MAOBADORA3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MCL1 900/4885KCNH2 2392/4885MAOB 2146/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | MCL1 900/4885KCNH2 2392/4885MAOB 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.